Immix Biopharma, Inc.
About Immix Biopharma, Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $20.0M
- Net income
- -$29.4M
- Total assets
- $104.8M
- Market cap
- $564.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $30.0M
- Operating income
- -$30.0M
- Income tax
- $37.7K
- Net income
- -$29.4M
- EPS (basic)
- $-0.89
- EPS (diluted)
- $-0.89
Balance sheet
- Total assets
- $104.8M
- Current assets
- $101.2M
- Total liabilities
- $11.0M
- Current liabilities
- $10.1M
- Shareholders’ equity
- $93.8M
Cash flow
- Operating cash flow
- -$23.9M
- Investing cash flow
- -$7.2M
- Financing cash flow
- $107.4M
- Net cash flow
- $76.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $564.5M
- EPS (diluted)
- $-0.89
- Shares outstanding
- 71.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 16, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $29.4M in FY2022.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Immix Biopharma, Inc..
Write a review
News about Immix Biopharma, Inc.
News & sentiment via Polygon.io
